ARCHIVES

Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 4 | April 29, 2011

Download PDF Visit The Full Archive

Related Articles

Second-Generation CML Drugs Show Promise For Frontline

December 26, 2008

NCI to Expand Quality of Care Research, Lead HHS Panel On Cancer Care Policy.

October 1, 1999

Herceptin Recommended As Adjuvant For HER2 Positive Early Breast Cancer

May 27, 2005

In Brief: Duke’s Gary Lyman to Co-Direct Fred Hutch Outcomes Research

January 10, 2014

Tobacco Council Awards 34 New Grants

April 16, 1982

In Brief: Progress Reported In NCI-FDA Fight Over New Drug Tests, Epidemiology Branch Reorganized

December 12, 1975